Macrophage inflammatory protein-3 alpha (MIP-3a) Is a novel serum prognostic marker in patients with colorectal cancer

Journal of Surgical Oncology

Volumn 107, Issue 2, 2013, Pages 160-166

  Iwata, Takashi ^a   Tanaka, Koji ^a   Inoue, Yasuhiro ^a   Toiyama, Yuji ^a   Hiro, Junichiro ^a   Fujikawa, Hiroyuki ^a   Okugawa, Yoshinaga ^a   Uchida, Keiichi ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

colorectal cancer; macrophage inflammatory protein 3 alpha; marker; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

ADOLESCENT; ADULT; AGED; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CHILD; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; SCHOOL CHILD; SERUM; TUMOR VOLUME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMOKINE CCL20; CHILD; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872261751     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23247     Document Type: Review

References (22)

1. Cunningham D, Atkin W, Lenz HJ, et al.: Colorectal cancer. Lancet 2010; 375: 1030-1047.
2. Gallagher DJ, Kemeny N:, Metastatic colorectal cancer: From improved survival to potential cure. Oncology 2010; 78: 237-248.
3. Platell C, Ng S, O'bichere A, et al.: Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum 2011; 54: 214-219.
4. Chau I, Cunningham D:, Treatment in advanced colorectal cancer: What, when and how ? Br J Cancer 2009; 100: 1704-1719.
5. Adam R, Haller DG, Poston G, et al.: Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-An expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 2010; 21: 1579-1584.
6. Watkins DJ, Chau I, Cunningham D, et al.: Defining patient outcomes in stage IV colorectal cancer: A prospective study with baseline stratification according to disease resectability status. Br J Cancer 2010; 102: 255-261.
7. Stillwell AP, Ho YH, Veitch C:, Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 2011; 35: 684-692.
8. Ghadjar P, Rubie C, Aebersold DM, et al.: The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 2009; 125: 741-745.
9. Schutyser E, Struyf S, Van Damme J:, The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409-426.
10. Mutch MG:, Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol 2007; 96: 693-703.
11. Oldenhuis CN, Oosting SF, Gietema JA, et al.: Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008; 44: 946-953.
12. Poston GJ, Figueras J, Giuliante F, et al.: Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26: 4828-4833.
13. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
14. Duffy MJ, van Dalen A, Haglund C, et al.: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-1360.
15. Hieshima K, Imai T, Opdenakker G, et al.: Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 1997; 272: 5846-5853.
16. Yang CC, Ogawa H, Dwinell MB, et al.: Chemokine receptor CCR6 transduces signals that activate p130Cas and alter cAMP-stimulated ion transport in human intestinal epithelial cells. Am J Physiol Cell Physiol 2005; 288: C321-C328.
17. Brand S, Olszak T, Beigel F, et al.: Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem 2006; 97: 709-723.
18. Rubie C, Frick VO, Wagner M, et al.: Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand J Immunol 2006; 63: 468-477.
19. Rubie C, Frick VO, Ghadjar P, et al.: CCL20/CCR6 expression profile in pancreatic cancer. J Transl Med 2010; 8: 45.
20. Chang KP, Hao SP, Chang JH, et al.: Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res 2008; 14: 6979-6987.
21. Rubie C, Oliveira V, Kempf K, et al.: Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol 2006; 27: 166-174.
22. Zitvogel L, Kepp O, Aymeric L, et al.: Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010; 70: 9538-9543.